{"id":"https://openalex.org/W2118921217","doi":"https://doi.org/10.1016/s0009-9236(97)90120-x","title":"Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*","display_name":"Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*","publication_year":1997,"publication_date":"1997-10-01","ids":{"openalex":"https://openalex.org/W2118921217","doi":"https://doi.org/10.1016/s0009-9236(97)90120-x","mag":"2118921217","pmid":"https://pubmed.ncbi.nlm.nih.gov/9357393"},"language":"en","primary_location":{"id":"doi:10.1016/s0009-9236(97)90120-x","doi":"https://doi.org/10.1016/s0009-9236(97)90120-x","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0009-9236(97)90120-x","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078314651","display_name":"David J. Kazierad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David J. Kazierad","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y., USA","Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y., USA","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088174722","display_name":"David E. Martin","orcid":"https://orcid.org/0000-0003-2820-5983","observed_orcids":["https://orcid.org/0000-0003-2820-5983"]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David E. Martin","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111914294","display_name":"Robert A. Blum","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Blum","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016048999","display_name":"David M. Tenero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Tenero","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050841518","display_name":"Bernard E. Ilson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bernard Ilson","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077900095","display_name":"Steven C. Boike","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven C. Boike","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050266240","display_name":"Rickey C. Etheredge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rickey Etheredge","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054853603","display_name":"Diane K. Jorkasky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110550","display_name":"Millard Fillmore Suburban Hospital","ror":"https://ror.org/01ska0k70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1325611130","https://openalex.org/I4210110550"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diane K. Jorkasky","raw_affiliation_strings":["Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y","institution_ids":["https://openalex.org/I4210110550"]},{"raw_affiliation_string":"Departments of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, Smith-Kline Beecham Pharmaceuticals, Philadelphia, Pa","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5078314651"],"corresponding_institution_ids":["https://openalex.org/I4210110550","https://openalex.org/I4210114143"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":4.5434,"has_fulltext":false,"cited_by_count":86,"citation_normalized_percentile":{"value":0.95539787,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"62","issue":"4","first_page":"417","last_page":"425"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9423999786376953,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.025800000876188278,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluconazole","display_name":"fluconazole","score":0.9990000128746033},{"id":"https://openalex.org/keywords/eprosartan","display_name":"eprosartan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/losartan","display_name":"losartan","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.875},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8650000095367432},{"id":"https://openalex.org/keywords/enzyme-inhibition","display_name":"enzyme inhibition","score":0.6309999823570251},{"id":"https://openalex.org/keywords/antifungal-agents","display_name":"antifungal agents","score":0.5789999961853027},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.8820000290870667},{"id":"https://openalex.org/keywords/steady-state-plasma-concentration","display_name":"steady-state plasma concentration","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C2780288358","wikidata":"https://www.wikidata.org/wiki/Q410074","display_name":"Losartan","level":4,"score":0.9716471433639526},{"id":"https://openalex.org/C2780651595","wikidata":"https://www.wikidata.org/wiki/Q411478","display_name":"Fluconazole","level":3,"score":0.8520736694335938},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.8374917507171631},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7704086303710938},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.6061868071556091},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.5880821943283081},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5736263990402222},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5607126355171204},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5476526021957397},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.44713446497917175},{"id":"https://openalex.org/C2778335254","wikidata":"https://www.wikidata.org/wiki/Q5137314","display_name":"Cmin","level":4,"score":0.41682004928588867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32364916801452637},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.12184828519821167},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.061591267585754395},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000179","descriptor_name":"Acrylates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000179","descriptor_name":"Acrylates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001189","descriptor_name":"Aryl Hydrocarbon Hydroxylases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003577","descriptor_name":"Cytochrome P-450 Enzyme System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003577","descriptor_name":"Cytochrome P-450 Enzyme System","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012016","descriptor_name":"Reference Values","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013250","descriptor_name":"Steroid Hydroxylases","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013250","descriptor_name":"Steroid Hydroxylases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015725","descriptor_name":"Fluconazole","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015725","descriptor_name":"Fluconazole","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D039181","descriptor_name":"Steroid 16-alpha-Hydroxylase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/s0009-9236(97)90120-x","doi":"https://doi.org/10.1016/s0009-9236(97)90120-x","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0009-9236(97)90120-x","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:9357393","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9357393","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1597211147","https://openalex.org/W1972212193","https://openalex.org/W1980716099","https://openalex.org/W2008984280","https://openalex.org/W2012019137","https://openalex.org/W2049104085","https://openalex.org/W2054862228","https://openalex.org/W2081882891","https://openalex.org/W2091224171","https://openalex.org/W2097712021","https://openalex.org/W2113602932","https://openalex.org/W2122428188","https://openalex.org/W2158657377","https://openalex.org/W2336891920","https://openalex.org/W4407013684"],"related_works":["https://openalex.org/W2078293971","https://openalex.org/W1980716099","https://openalex.org/W2033582596","https://openalex.org/W2057671728","https://openalex.org/W2520289034","https://openalex.org/W1995097670","https://openalex.org/W2126699980","https://openalex.org/W1833059984","https://openalex.org/W2159556641","https://openalex.org/W2072116635"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"investigate":[2],"the":[3,10,103,172,179,182,196],"effect":[4,194],"of":[5,12,80,83,91,111,164,175,181,185,199],"steady-state":[6,173,197],"fluconazole":[7,50,190],"administration":[8,128,163,191],"on":[9,38,55,72,195],"disposition":[11],"eprosartan,":[13,84],"losartan,":[14,85,186],"and":[15,29,58,76,86,123,133,139,151,159,177],"E-3174.":[16,187],"METHODS:":[17],"Sixteen":[18],"healthy":[19],"male":[20],"subjects":[21,46],"received":[22,31,47],"300":[23],"mg":[24,33,49],"eprosartan":[25,100],"every":[26,35,51],"12":[27],"hours,":[28],"16":[30],"100":[32],"losartan":[34,131,147,165,176],"24":[36,52],"hours":[37,53],"study":[39,73],"days":[40,74],"1":[41],"to":[42,109],"20.":[43,62],"All":[44],"32":[45],"200":[48],"beginning":[54],"day":[56,61],"11":[57],"continuing":[59],"through":[60],"Serial":[63],"blood":[64],"samples":[65],"were":[66,135,155],"collected":[67],"over":[68],"one":[69],"dosing":[70],"interval":[71],"10":[75],"20":[77],"for":[78,146,153],"measurement":[79],"plasma":[81],"concentrations":[82],"E-3174":[87,154],"(the":[88],"active":[89,183],"metabolite":[90,184],"losartan).":[92],"RESULTS:":[93],"There":[94],"was":[95],"no":[96,193],"significant":[97],"difference":[98],"in":[99],"area":[101],"under":[102],"concentration-time":[104],"curve":[105],"from":[106],"time":[107,110],"0":[108],"last":[112],"quantifiable":[113],"concentration":[114,118],"[AUC(0-t)]":[115],"or":[116],"maximum":[117],"(Cmax)":[119],"when":[120],"administered":[121],"alone":[122],"with":[124,129,143,166],"fluconazole.":[125,167],"After":[126],"concomitant":[127],"fluconazole,":[130],"AUC(0-t)":[132,150],"Cmax":[134,152],"significantly":[136,156,170],"increased":[137],"66%":[138],"30%,":[140],"respectively,":[141,161],"compared":[142],"those":[144],"values":[145],"alone.":[148],"The":[149],"decreased":[157],"43%":[158],"56%,":[160],"after":[162],"CONCLUSIONS:":[168],"Fluconazole":[169],"increases":[171],"AUC":[174],"inhibits":[178],"formation":[180],"In":[188],"contrast,":[189],"has":[192],"pharmacokinetics":[198],"eprosartan.":[200]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}